Scientists uncover new function of a key protein – target of potent anti-cancer therapy
Dr. Radoslav Alexandrov and Assoc. Prof. Stoyno Stoynov PARP inhibitors are anticancer drugs that selectively inhibit the growth of tumors with deficiencies in DNA repair capacity, and are being approved for a growing number of indications. A deeper understanding of the mechanisms of action of PARP inhibitors as well as the function of their target PARP1 represent a hot topic in molecular oncology. Scientists from the Genomic Stability Laboratory and the Sofia Eurobioimaging Center for Advanced Light Microscopy at the Institute of Molecular Biology-BAS (IMB-BAS) are part of a thirteen-member interdisciplinary team that published a study on "PARP1-DNA co-condensation drives DNA repair site assembly to prevent disjunction of broken DNA ends" in one of the three most prestigious journals in the world of [...]
